• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定氯法齐明作为药物转运体的潜在底物。

Characterization of Clofazimine as a Potential Substrate of Drug Transporter.

机构信息

Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Republic of Korea.

Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.

出版信息

Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0215821. doi: 10.1128/aac.02158-21. Epub 2022 Mar 7.

DOI:10.1128/aac.02158-21
PMID:35254089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9017350/
Abstract

In this study, we explored clofazimine (CFZ) as a potential substrate of uptake and efflux transporters that might be involved in CFZ disposition, using transporter gene overexpressing cell lines . The intracellular concentrations of CFZ were significantly increased in the presence of selective inhibitors of P-gp and BCRP, which include verapamil, cyclosporine-A, PSC-833, quinidine, Ko143, and daunorubicin. In a bidirectional transport assay using transwell cultures of cell lines overexpressing P-gp and BCRP, the mean efflux ratios of CFZ were found to be 4.17 ± 0.63 and 3.37 ± 1.2, respectively. The and maximum rate of uptake () were estimated to be 223.3 ± 14.73 μM and 548.8 ± 87.15 pmol/min/mg protein for P-gp and 381.9 ± 25.07 μM and 5.8 ± 1.22 pmol/min/mg protein for BCRP, respectively. Among the uptake transporters screened, the CFZ uptake rate was increased 1.93 and 3.09-fold in HEK293 cell lines overexpressing OAT1 and OAT3, respectively, compared to the control cell lines, but no significant uptake was observed in cell lines overexpressing OCT1, OCT2, OATP1B1, OATP1B3, OATP2B1, or NTCP. Both OAT1- and OAT3-mediated uptake was inhibited by the selective inhibitors diclofenac, probenecid, and butanesulfonic acid. The and values of CFZ were estimated to be 0.63 ± 0.15 M and 8.23 ± 1.03 pmol/min/mg protein, respectively, for OAT1 and 0.47 ± 0.1 μM and 17.81 ± 2.19 pmol/min/mg protein, respectively, for OAT3. These findings suggest that CFZ is a novel substrate of BCRP, OAT1, and OAT3 and a known substrate of P-gp .

摘要

在这项研究中,我们使用过表达转运体基因的细胞系探索氯法齐明(CFZ)是否为可能参与 CFZ 处置的摄取和外排转运体的潜在底物。在存在 P-糖蛋白和 BCRP 选择性抑制剂(包括维拉帕米、环孢素 A、PSC-833、奎尼丁、Ko143 和柔红霉素)的情况下,CFZ 的细胞内浓度显著增加。在使用过表达 P-糖蛋白和 BCRP 的细胞系的 Transwell 培养物进行的双向转运测定中,CFZ 的平均外排比分别为 4.17 ± 0.63 和 3.37 ± 1.2。P-糖蛋白和 BCRP 的摄取 和最大速率()分别估计为 223.3 ± 14.73 μM 和 548.8 ± 87.15 pmol/min/mg 蛋白和 381.9 ± 25.07 μM 和 5.8 ± 1.22 pmol/min/mg 蛋白。在筛选的摄取转运体中,与对照细胞系相比,CFZ 的摄取率在过表达 OAT1 和 OAT3 的 HEK293 细胞系中分别增加了 1.93 倍和 3.09 倍,但在过表达 OCT1、OCT2、OATP1B1、OATP1B3、OATP2B1 或 NTCP 的细胞系中未观察到明显摄取。OAT1 和 OAT3 介导的摄取均被选择性抑制剂双氯芬酸、丙磺舒和丁烷磺酸抑制。CFZ 的 和 值分别估计为 OAT1 为 0.63 ± 0.15 μM 和 8.23 ± 1.03 pmol/min/mg 蛋白,OAT3 为 0.47 ± 0.1 μM 和 17.81 ± 2.19 pmol/min/mg 蛋白。这些发现表明 CFZ 是 BCRP、OAT1 和 OAT3 的新型底物,也是 P-糖蛋白的已知底物。

相似文献

1
Characterization of Clofazimine as a Potential Substrate of Drug Transporter.鉴定氯法齐明作为药物转运体的潜在底物。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0215821. doi: 10.1128/aac.02158-21. Epub 2022 Mar 7.
2
Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.有机阴离子转运体3、有机阴离子转运多肽1B1和1B3介导的梓醇转运
Drug Des Devel Ther. 2015 Jan 22;9:643-53. doi: 10.2147/DDDT.S75400. eCollection 2015.
3
Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.体外参与贝拉前列素钠转运的转运体的鉴定
Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):117-128. doi: 10.1007/s13318-016-0327-4.
4
Evaluation of -Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs .对氨基水杨酸作为多种溶质载体摄取转运体底物的评估以及与非甾体抗炎药可能存在的药物相互作用。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02392-16. Print 2017 May.
5
Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.缬沙坦、沙库巴曲及其活性代谢物(LBQ657)的转运特性作为处置的决定因素。
Xenobiotica. 2018 Mar;48(3):300-313. doi: 10.1080/00498254.2017.1295171. Epub 2017 Mar 10.
6
Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.雷特格韦通过抑制主要药物转运体导致临床药物相互作用的倾向较低:一项体外评估
Antimicrob Agents Chemother. 2014;58(3):1294-301. doi: 10.1128/AAC.02049-13. Epub 2013 Dec 2.
7
In vitro evaluation of potential transporter-mediated drug interactions of evogliptin.依格列净潜在转运体介导的药物相互作用的体外评价
Biopharm Drug Dispos. 2017 Sep;38(6):398-403. doi: 10.1002/bdd.2083. Epub 2017 Jul 13.
8
Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.木犀草素与溶质载体转运蛋白和 ATP 结合盒转运蛋白的相互作用:该黄酮类化合物的药物转运体特征。
Chem Biol Interact. 2020 Jun 1;324:109097. doi: 10.1016/j.cbi.2020.109097. Epub 2020 Apr 16.
9
Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor.口服强效聚(ADP-核糖)聚合酶抑制剂鲁卡帕尼的吸收、分布、代谢和排泄评估以及药物相互作用评价
Xenobiotica. 2020 Sep;50(9):1032-1042. doi: 10.1080/00498254.2020.1737759. Epub 2020 Mar 18.
10
Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07.抗恶病质候选化合物 TCMCB07 的细胞转运机制特征。
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1677-1687. doi: 10.1002/jcsm.12602. Epub 2020 Jul 29.

本文引用的文献

1
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.中国西南地区耐左氧氟沙星、莫西沙星、贝达喹啉、利奈唑胺、氯法齐明和德拉马尼的耐多药结核分枝杆菌的分子特征。
BMC Infect Dis. 2021 Apr 8;21(1):330. doi: 10.1186/s12879-021-06024-8.
2
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.世界卫生组织关于耐药结核病治疗的建议,2020年更新版。
Eur Respir J. 2021 Jun 4;57(6). doi: 10.1183/13993003.03300-2020. Print 2021 Jun.
3
Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective.瑞德西韦与肺部药物的潜在相互作用:从新冠肺炎角度看
SN Compr Clin Med. 2020;2(10):1707-1708. doi: 10.1007/s42399-020-00462-2. Epub 2020 Aug 21.
4
Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters .对多种溶质载体(SLC)摄取转运蛋白的 22 种抗结核药物进行全面的底物特征分析。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00512-18. Print 2018 Sep.
5
Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches.采用静态和动态建模方法评估氯法齐明的临床药物相互作用潜力。
Drug Metab Dispos. 2018 Jan;46(1):26-32. doi: 10.1124/dmd.117.077834. Epub 2017 Oct 16.
6
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.22种抗结核药物对SLC22A家族有机阴离子和阳离子转运体的抑制相互作用潜力
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6558-6567. doi: 10.1128/AAC.01151-16. Print 2016 Nov.
7
Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.22种抗结核药物对有机阴离子转运多肽(OATP)介导摄取的抑制相互作用潜力的表征
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3096-105. doi: 10.1128/AAC.02765-15. Print 2016 May.
8
Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.抗结核药物对ATP结合盒式药物转运体的抑制潜力。
Tuberculosis (Edinb). 2016 Jan;96:150-7. doi: 10.1016/j.tube.2015.08.004. Epub 2015 Oct 9.
9
Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.多奈哌齐与西洛他唑在乳腺癌耐药蛋白(ABCG2)处的局部药物相互作用增加了心脏中的药物蓄积。
Drug Metab Dispos. 2016 Jan;44(1):68-74. doi: 10.1124/dmd.115.066654. Epub 2015 Oct 14.
10
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.喀麦隆针对耐多药结核病患者的12个月治疗方案具有高效性。
Int J Tuberc Lung Dis. 2015 May;19(5):517-24. doi: 10.5588/ijtld.14.0535.